Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 18/20 | 0.68 |
| ▸ | MMP1 | P03956 | 15/20 | 0.68 |
| ▸ | MMP7 | P09237 | 13/20 | 0.68 |
| ▸ | MMP13 | P45452 | 10/20 | 0.68 |
| ▸ | MMP2 | P08253 | 8/20 | 0.68 |
| ▸ | MMP8 | P22894 | 5/20 | 0.66 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237447 | 0.94 | MMP3 (0.63) | MMP3MMP1MMP7MMP13MMP2 | |
| SCHEMBL7238718 | 0.94 | MMP3 (0.71) | MMP3MMP1MMP7MMP13MMP2 | |
| SCHEMBL7235966 | 0.92 | MMP3 (0.73) | MMP3MMP1MMP7MMP13MMP2 | |
| SCHEMBL7235599 | 0.91 | MMP3 (0.67) | MMP3MMP1MMP7MMP13MMP2 | |
| SCHEMBL7247592 | 0.90 | MMP3 (0.61) | MMP3MMP1MMP7MMP13MMP2 | |
| SCHEMBL7236932 | 0.90 | MMP3 (0.61) | MMP3MMP1MMP7MMP13MMP2 | |
| SCHEMBL7236822 | 0.89 | MMP3 (0.67) | MMP3MMP1MMP7MMP13MMP2 | |
| SCHEMBL7236255 | 0.88 | MMP3 (0.67) | MMP3MMP1MMP7MMP13MMP2 | |
| SCHEMBL7241651 | 0.88 | MMP3 (0.61) | MMP3MMP1MMP7MMP13MMP2 | |
| SCHEMBL7235608 | 0.88 | MMP3 (0.74) | MMP3MMP1MMP7MMP13MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229113-A1 | Keratinocyte growth inhibitors and hydroxamic acid derivatives | AKZO NOBEL N.V. (NL) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229113-A1 | Keratinocyte growth inhibitors and hydroxamic acid derivatives | FGF1, FGF2, EGFR | MMP3 79/4885MMP1 60/4885MMP7 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.